Dr. Reddy's Q2FY27 Revenue at ₹8,671 Cr, EBITDA at ₹1,783 Cr
Dr. Reddy's Laboratories reported Q2FY27 revenues of ₹8,671 crore, up 1.5% YoY. EBITDA surged 24% YoY to ₹1,783 crore with a 20.6% margin. PAT was ₹925 crore, up 36% YoY. The company partnered with Takeda for a dengue vaccine launch in H1 2027 and its CDMO business exceeded $100 million in annualized revenue.
The reported financial results, including revenue and profit growth, along with significant strategic partnerships and regulatory approvals, are material to the company's performance and investor outlook.
The company reported strong financial results with increased revenues and significant growth in EBITDA and PAT. Positive developments in strategic partnerships and business expansions also contribute to a positive sentiment.
Dr. Reddy's Laboratories Limited announced its Unaudited Financial Results for the quarter and half year ended September 30, 2026. The company reported revenues of ₹8,671 crore, marking a 1.5% year-on-year (YoY) increase and a 7% quarter-on-quarter (QoQ) rise. EBITDA stood at ₹1,783 crore, a significant 24% YoY increase and a 77% QoQ jump, with an EBITDA margin of 20.6%.
Profit Before Tax (PBT) was ₹1,228 crore (14.2% of revenue), up 33% YoY and 122% QoQ. Profit After Tax (PAT) attributable to equity shareholders was ₹925 crore (10.7% of revenue), an increase of 36% YoY and 109% QoQ. The company maintained a double-digit underlying base business growth, excluding lenalidomide sales in North America. The net cash surplus was ₹2,502 crore.
Key business highlights include a partnership with Takeda for the launch of the CDSCO-approved dengue vaccine, QDENGA, in India in H1 2027. The company also expanded its collaboration with Gilead Sciences for lenacapavir and secured approval for its rituximab biosimilar from the USFDA. The CDMO business under Aurigene Pharmaceutical Services surpassed $100 million in annualized revenues.
The company received a 'Silver' medal from FinanceAsia for 'Best Large Cap Company in India' and improved its CRISIL ESG Rating to 73/100 for FY26. Dr. Reddy's is on track to resolve the issue associated with semaglutide API and received 'VAI' classification for its API manufacturing facility in Mirfield, UK, following a USFDA inspection. The company also addressed Form 483 observations from USFDA inspections at its Srikakulam and Hyderabad facilities, and a Form 2953 from a records assessment in Mexico, responding within stipulated timelines.
What to do with a filing like this
Dr. Reddy's Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Dr. Reddy's Laboratories Limited. Read the original for the full detail.